CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
暂无分享,去创建一个
R. Greil | R. Weinshilboum | M. Gnant | C. Reynolds | M. Goetz | J. Ingle | R. Jakesz | V. Suman | M. Filipits | M. Ames | F. Offner | T. Hoskin | O. Dietze | M. Rudas | Stephanie L. Safgren | M. Kuffel | A. Lang
[1] J. Cuzick,et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. , 2012, Journal of the National Cancer Institute.
[2] P. Neven,et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. , 2012, Journal of the National Cancer Institute.
[3] R. Greil,et al. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] H. Brauch,et al. CYP2D6 and tamoxifen: awaiting the denouement. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] L. Natarajan,et al. Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes , 2011, Clinical pharmacology and therapeutics.
[6] T. Fehm,et al. Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma , 2011, Clinical pharmacology and therapeutics.
[7] K. Lunetta,et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. , 2011, Journal of the National Cancer Institute.
[8] Zeruesenay Desta,et al. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. , 2010, British journal of clinical pharmacology.
[9] T. Trikalinos,et al. CYP2D6 testing to predict response to tamoxifen in women with breast cancer , 2010, PLoS currents.
[10] C. Caldas,et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen , 2010, Breast Cancer Research.
[11] J. Griggs,et al. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. , 2010, Journal of oncology practice.
[12] R. Weinshilboum,et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Cuzick,et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Soonmyung Paik,et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.
[15] M. Beckmann,et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. , 2009, JAMA.
[16] Sally Hunsberger,et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Fergus J Couch,et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Lippman. Adherence to medication. , 2005, The New England journal of medicine.
[19] Michael Gnant,et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial , 2005, The Lancet.
[20] David A. Flockhart,et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.
[21] David A. Flockhart,et al. Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.
[22] T. Skaar,et al. Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.
[23] Zeruesenay Desta,et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.
[24] Y. Nakamura,et al. Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] J. Gusella,et al. A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. , 2000, Cancer research.
[26] M. Eichelbaum,et al. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. , 1991, American journal of human genetics.
[27] Paul R. Rosenbaum,et al. Optimal Matching for Observational Studies , 1989 .
[28] G. H. Bush,et al. Pharmacogenetics , 1968 .
[29] H. Kang,et al. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment , 2011, Breast Cancer Research and Treatment.
[30] T. Trikalinos,et al. CYP2D6 testing to predict response to tamoxifen in women with breast cancer. Pharmacogenomic. , 2010, PLoS currents.
[31] J. Rowland. 4–48 Early Discontinuation of Tamoxifen: A Lesson for Oncologists , 2008 .